BioTime (BTX) Reports Q4 Loss of $0.58/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. SPY
9. FIX
10. NDAQ

Go back to BioTime (BTX) Reports Q4 Loss of $0.58/Share

BioTime Reports Fourth Quarter and Fiscal 2017 Results

March 15, 2018 4:06 PM EDT

Renevia® CE Mark application submitted for European approval OpRegen® receives DSMB approval to proceed to cohort 4 OpRegen® cohort 4 will include better vision patients and an array of additional functional assessments

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017.

2017 was a successful year for BioTime, capped by our recent European CE Mark submission of Renevia® and... More